<DOC>
	<DOCNO>NCT01556789</DOCNO>
	<brief_summary>Open label , two part , Phase 1 dose escalation study evaluate safety immunogenicity repeat dose vaccination ONT-10 patient previously treat Stage 3 4 solid tumor . Part 1 evaluate escalate dose level ONT-10 administer subcutaneously every two week ( Q2W ) weekly ( QW ) 8 week . Part 2 evaluates safety , immunogenicity , potential anti-tumor activity ONT-10 administer 8 week Q2W QW maximum tolerate does/recommended dose ( MTD/RD ) cohorts 15 patient .</brief_summary>
	<brief_title>Phase 1 Study ONT-10 Patients With Solid Tumors</brief_title>
	<detailed_description>This open label , two part , Phase 1 dose escalation study evaluate safety immunogenicity repeat dose vaccination ONT-10 patient previously treat Stage 3 4 solid tumor histology associate expression MUC1 antigen describe medical literature . Part 1 evaluate escalate dose level ONT-10 administer subcutaneously Q2W 8 week ( total 4 dos ) QW 8 week ( total 8 dos ) identify MTD and/or RD dosing schedule , evaluation Part 2 study . Part 2 evaluate safety , immunogenicity , potential anti-tumor activity ONT-10 administer 8 week Q2W QW MTD/RD cohorts 15 patient .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Be 18 70 year age time consent 2 . Life expectancy least 6 month , opinion investigator 3 . A ) Have histologically confirm breast , nonsmall cell lung , ovarian , colorectal , gastric , prostate , pancreatic , renal cell cancer , tumor type approve study medical monitor ( Part 1 ) B ) Have histologically confirm breast ovarian carcinoma ( Part 2 ) 4 . Have evidence persistent , recurrent , progressive disease least one course systemic therapy locally advance metastatic disease , include chemotherapy , target therapy , immunotherapy 5 . Clinical stage 3 4 disease 6 . ECOG 0 1 7 . Adequate baseline hematological parameter define white blood cell count ( WBC ) ≥ 3.5 x 103/uL , lymphocyte count ≥ 1.0 x 103/uL , platelet count ≥ 100 x 103/uL , hemoglobin ≥ 9 g/dL 8 . Have renal hepatic function laboratory test result exceed 1.5 X upper limit normal ( ULN ) 9 . If female child bear potential , negative pregnancy test screen 10 . If fertile male female childbearing potential , agree consistently use highly effective method birth control ( include birth control pill , barrier device , intrauterine device ) time consent 3 month follow last dose study drug . 11 . Be able willing sign inform consent document approve institutional review board independent ethic committee ( IRB/IEC ) 1 . Has medical , social , psychosocial factor , opinion investigator , could impact safety compliance study procedures 2 . Is pregnant , breastfeeding , plan pregnancy 3 . Has receive treatment systemic chemotherapy , radiation , experimental agent within 4 week study drug dose 4 . Has untreated uncontrolled central nervous system ( CNS ) metastasis , include patient require glucocorticoid therapy CNS metastasis . 5 . Has know history autoimmune disease , arteritis , vasculitis , include , limited : lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease ( include ulcerative colitis Crohn 's disease ) , Grave 's disease , Hashimoto 's thyroiditis , Wegener 's granulomatosis , temporal arteritis , polyarteritis nodosa 6 . Has recognize immunodeficiency disease , include cellular immunodeficiency , hypogammaglobulinemia , dysgammaglobulinemia ; and/or hereditary congenital immunodeficiency 7 . Has preexist medical condition require chronic steroid immunosuppressive therapy ( corticosteroid COPD topical steroid allow ) 8 . Known positive HIV , hepatitis B , hepatitis C 9 . Administration vaccine ≤ 4 week prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>ONT-10</keyword>
	<keyword>MUC1</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Dose escalation</keyword>
</DOC>